-
Chardan Sees Spark Therapeutics PLA Amendments As Positive For Consolidating IP, Warns Of Risks Associated With Existing Issued Patent
Friday, January 8, 2016 - 3:39pm | 320Read More...Spark Therapeutics Inc (NASDAQ: ONCE)'s Patent License Agreement (PLA) amendments were viewed as "positive" for consolidating IP by analysts at Chardan Capital Markets; however, the firm also warned of risks associated with its existing issued patent. Consolidating IP "The action is positive in...
-
Analysts Aren't Sure What To Do With Ambarella After Earnings
Friday, December 4, 2015 - 12:12pm | 399Read More...Ambarella Inc (NASDAQ: AMBA)'s stock is surging in Friday's trading following its Q3 earnings report. Analysts on Wall Street have mixed feelings about what they saw from the company in Q3. Despite a big earnings beat, Ambarella's Q4 guidance was relatively weak. Shares of...
-
Why '16 Will Be A Year Of Major New Product Introductions For Vuzix
Friday, December 4, 2015 - 10:30am | 290Read More...Shares of Vuzix Corporation (NASDAQ: VUZI) were volatile in 2015 and are up 45 percent year-to-date. Chardan’s James Mcilree maintained a Buy rating on the company, with a price target of $7. The company is on the brink of a new product cycle and poised for robust sales growth,...
-
Chardan Stays On The Sidelines Of Ambarella
Friday, December 4, 2015 - 9:40am | 296Read More...Ambarella Inc (NASDAQ: AMBA) shares have been volatile so far in 2015, and have gained 14 percent year-to-date. Chardan’s Marc Estigarribia maintained a Hold rating on the company, while establishing a price target of $90. Although the company delivered an earnings beat, its...
-
Chardan's Take On Axovant, Avalanche & VistaGen
Monday, July 27, 2015 - 12:47pm | 426Read More...Editor's note: A previous version of this article said Chardan held a $10 price target on VistaGen. This information was incorrect and has been removed. The firm holds a $50 price target on the stock. A new report out this week by Chardan Capital Management focuses on three biotech stocks that...
-
Chardan Reiterates Sell On Axovant
Thursday, July 23, 2015 - 1:50pm | 297Read More...In a report published Thursday, Chardan Capital Markets analyst Gbola Amusa commented on Axovant Sciences Ltd (NYSE: AXON) following the company's completer analysis from a previously-published phase IIb which were "less robust scientifically" and "less relevant to the...
-
Chardan: Vislab Won't Give Ambarella Material Revenue Until 2017
Thursday, July 2, 2015 - 1:48pm | 254Read More...Chardan's Managing Director of Equity Research, Jay Srivatsa, said in a note that Ambarella Inc (NASDAQ: AMBA)'s acquisition of Vislab extends the company's "available market," but will not bring in "material product revenues" until 2017. Srivatsa said that it...
-
Chardan Initiates Integrated Device Technology At Buy
Thursday, January 15, 2015 - 10:16am | 64Read More...Analysts at Chardan initiated coverage on Integrated Device Technology Inc (NASDAQ: IDTI) with a Buy rating. The target price for Integrated Device Technology is set to $22. Integrated Device Technology shares have jumped 60.98% over the past 52 weeks, while the S&P 500 index has gained 8.96...
-
UPDATE: Chardan Initiates Coverage On Integrated Device Technology On Position To Benefit From High-Growth Markets
Thursday, January 15, 2015 - 10:07am | 124Read More...In a report published Thursday, Chardan analyst Jay Srivatsa initiated coverage on Integrated Device Technology Inc (NASDAQ: IDTI) with a Buy rating and $22.00 price target. In the report, Chardan noted, “We are positive on IDTI's fundamentals as the company is expected to book order inflow for new...
-
Chardan Analyst: Microsoft, Google 'Big Losers' In Las Vegas
Monday, January 12, 2015 - 5:09pm | 346Read More...Google Inc (NASDAQ: GOOG)(NASDAQ: GOOGL) and Microsoft Corporation (NASDAQ: MSFT) were big losers at a a recent Las Vegas consumer electronics show, an analyst said Monday. With about 180,000 in attendance at the annual show, the absence of compelling products from the two giant companies was...
-
SEED Upgraded To Buy At Chardan
Friday, May 28, 2010 - 8:46am | 46Read More...Analysts at Chardan upgrade Origin Agritech (NASDAQ: SEED) from "neutral" to "buy." The target price for SEED is set to $18. SEED’s shares closed at $8.09 yesterday. More Analyst Ratings here
